KODIAK SCIENCES INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
KODIAK SCIENCES INC. (KOD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$83.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$40.33M.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$29.22M.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$39.73M, a 131.48% decline year-over-year.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $126.18M.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $41.79M.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$117.57M, a 223.66% decline from fiscal 2023.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $95.07M.
- KODIAK SCIENCES INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$541.08M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$83.96M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$40.33M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $41.79M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$96.04M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$63.91M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$29.22M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$117.57M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$87.78M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$66.42M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$39.73M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $95.07M 10-K · filed 2026-03-31 | |||
| 2023-09-30 | $155.24M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $188.24M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $126.18M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$541.08M 10-K · filed 2025-03-27 | |||
| 2022-09-30 | -$553.10M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$558.82M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$59.78M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$212.89M 10-K · filed 2024-03-28 | |||
| 2021-09-30 | -$145.15M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$63.53M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$23.93M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $738.78M 10-K · filed 2023-03-28 | |||
| 2020-09-30 | $90.66M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $58.04M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $14.66M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $123.54M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$51.22M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$43.29M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$31.03M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $86.86M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $10.20M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $16.25M 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $21.42M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$8.23M 10-K · filed 2020-03-16 | |||
| 2017-09-30 | -$3.23M 10-Q · filed 2018-11-16 | |||
| 2016-12-31 | -$16.94M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |